Injectable 2D MoS2 -Integrated Drug Delivering Implant for Highly Efficient NIR-Triggered Synergistic Tumor Hyperthermia.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26447460.
- Also identified by DOI 10.1002/adma.201503869.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
MoS2 nanosheets and a doxorubicin (DOX)-containing poly (lactic-co-glycolic acid) (PLGA)/MoS2 /DOX composite implant are successfully constructed based on the unique phase-changing behavior of PLGA/MoS2 /DOX oleosol within tumors. The fast phase transformation can firmly restrict MoS2 and DOX within tumors, and the integrated MoS2 and DOX can endow the implant with high synergistic photothermal and chemotherapeutic efficiency against tumors.
Medical subject headings
- Disulfides
- Drug Carriers
- Hyperthermia, Induced
- Infrared Rays
- Molybdenum
- Neoplasms